Minerva Neurosciences, Inc.
NERV
$4.73
-$0.01-0.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -28.09% | -57.75% | 14.20% | -10.09% | 20.41% |
| Gross Profit | 28.09% | 57.75% | -14.20% | 10.09% | -20.41% |
| SG&A Expenses | 82.64% | -6.09% | -7.98% | -3.83% | -2.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.16% | -30.87% | -40.23% | -38.32% | -22.02% |
| Operating Income | -46.16% | 30.87% | 40.23% | 38.32% | 22.02% |
| Income Before Tax | -6,736.20% | -20,492.20% | -323.59% | 133.38% | 119.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6,736.20% | -20,492.20% | -323.59% | 133.38% | 119.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6,736.20% | -20,492.20% | -323.59% | 133.38% | 119.79% |
| EBIT | -46.16% | 30.87% | 40.23% | 38.32% | 22.02% |
| EBITDA | -46.17% | 30.88% | 40.23% | 38.33% | 22.02% |
| EPS Basic | -3,629.03% | -14,199.47% | -323.59% | 133.38% | 118.44% |
| Normalized Basic EPS | -3,629.73% | -14,212.89% | -323.55% | 133.37% | 118.44% |
| EPS Diluted | -3,647.92% | -14,533.55% | -318.52% | 133.27% | 118.34% |
| Normalized Diluted EPS | -3,629.73% | -14,212.89% | -323.55% | 133.37% | 118.44% |
| Average Basic Shares Outstanding | 131.72% | 11.72% | 0.00% | 0.00% | 7.29% |
| Average Diluted Shares Outstanding | 131.72% | 11.72% | 0.00% | 0.00% | 7.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |